Helix BioPharma (TSE:HBP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Helix BioPharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor from Laevoroc Immunology AG, enhancing its immune-oncology portfolio. This transaction will involve issuing 16.5% of Helix’s shares to acquire intellectual property and assets, pending regulatory approval. The move aims to expand Helix’s pipeline with promising therapeutic candidates for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.